Evotec SEXSWX:EVT +4.02%68 Return-on-Tangible-Equity is -106.40% as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 896 Drug Manufacturers companies, Evotec SE ranks worse than 89.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Evotec SE's annualized net income for the quarter that ended in Mar. 2026 was CHF-443.9 Mil. Evotec SE's average shareholder tangible equity for the quarter that ended in Mar. 2026 was CHF417.2 Mil. Therefore, Evotec SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -106.40%.
The historical rank and industry rank for Evotec SE's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:EVT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -38.03 Med: 14.49 Max: 302.41
Current: -38.03
During the past 13 years, Evotec SE's highest Return-on-Tangible-Equity was 302.41%. The lowest was -38.03%. And the median was 14.49%.
XSWX:EVT's Return-on-Tangible-Equity is ranked worse than 89.29% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs XSWX:EVT: -38.03
Evotec SE (XSWX:EVT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Evotec SE Return-on-Tangible-Equity Related Terms
Evotec SE Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Evotec SE's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EVT vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Evotec SE's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -106.40% mean?
Evotec SE (XSWX:EVT) has a Return-on-Tangible-Equity of -106.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #800 out of 896 companies in the Drug Manufacturers industry, placing it in the top 89.3%.
Is Evotec SE's Return-on-Tangible-Equity too high?
Evotec SE's current Return-on-Tangible-Equity is -106.40%. Based on the distribution chart, Evotec SE ranks #800 out of 896 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #800 out of 896 companies for Return-on-Tangible-Equity. This places Evotec SE in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Return-on-Tangible-Equity is -106.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Return-on-Tangible-Equity is -106.40%. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Return-on-Tangible-Equity is -106.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
Return-on-Tangible-Equity: -106.40%
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
